Results 251 to 260 of about 1,318,851 (362)

Acupuncture as adjunctive therapy for acute cerebral infarction: a randomized clinical trial. [PDF]

open access: yesFront Neurol
Cao JP   +14 more
europepmc   +1 more source

Targeting TRPV4 to restore glymphatic system function and alleviate cerebral edema in ischemic stroke

open access: yesBrain Pathology, EarlyView.
After ischemic stroke, TRPV4 activation induces cerebral edema through the TRPV4‐RhoA‐MMP9 axis: RhoA upregulates MMP9, which cleaves β‐DG to impair membrane anchoring. Subsequent β‐DG loss triggers AQP4 depolarization, disrupting GS‐mediated water homeostasis.
Yongchuan Li   +13 more
wiley   +1 more source

1 H-NMR-Based Metabolomics Study of Cerebral Infarction

open access: yesStroke, 2011
Jeeyoun Jung   +7 more
semanticscholar   +1 more source

Contribution of α‐synuclein cytopathologies to distinct seeding of misfolded α‐synuclein

open access: yesBrain Pathology, EarlyView.
This study investigated whether brain regions with distinct predominance of α‐synuclein (αSyn) cytopathologies show different αSyn seeding patterns in multiple system atrophy (MSA) and Lewy body disease (LBD), using an interdisciplinary approach. High seeding activity is observed in regions with oligodendrocytic‐predominant αSyn pathology in MSA.
Ain Kim   +4 more
wiley   +1 more source

Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.

open access: yesBritish medical journal, 1989
J. Pickard   +9 more
semanticscholar   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy